PanTum® Detect - A multi-tumor screening blood test for asymptomatic healthy individuals
Find tumors before it is too late !

Get screened with PanTum® Detect today
The best cure for cancer is to detect silently growing tumors before they become dangerous
bt_bb_section_bottom_section_coverage_image

Disruptive German EDIM Technology Platform Now in India

Leverages the immune system to uncover ALL solid organ cancer types, before symptoms appear in healthy persons

The Problem

Cancer is usually detected in late stages

A vast majority of cancers show no symptoms until late stages, when treatment is complex, painful, traumatic, with poor clinical outcomes and high medical costs.

 

https://www.medidect.com/wp-content/uploads/2023/08/Medidect-03.png

^ Diagnostic and treatment cost are estimates based on mapping of private hospital costs with cancer diagnostic & treatment pathways per stage of detection

India’s cancer reality

https://www.medidect.com/wp-content/uploads/2024/01/WHO-Logo-320x180.png
1 in 10 Indians will develop cancer during their lifetime
https://www.medidect.com/wp-content/uploads/2024/01/Picture1-640x135.png

*Source: https://www.hindustantimes.com/india-news/one-in-10-indians-will-develop-cancer-during-their-lifetime-who/story-NcNQhPTS01YWI9Qovfcy5J.html

https://www.medidect.com/wp-content/uploads/2024/01/Indian_Council_of_Medical_Research_Logo.svg_-e1705310373624-320x140.png
1 in 9 Indians will develop cancer during their lifetime
https://www.medidect.com/wp-content/uploads/2024/01/Picture2-640x150.png

*Source: https://www.hindustantimes.com/lifestyle/health/cancer-risk-factors-here-s-why-indians-are-at-a-higher-risk-of-the-disease-101675603191553.html

Only 6 out of over 200 types of cancer have validated cancer specific screening interventions globally

https://www.medidect.com/wp-content/uploads/2024/01/PanTumAsset-3.png

Only 6 out of over 200 types of cancer have validated cancer specific screening interventions globally

India lacks screening protocols for cost-effective screening for multiple cancers within ONE structured Preventive Oncology Program.

Cancer is a financially draining silent killer with low survival rates for tumor growth that advances undetected till later stages.

Cancer is a financially draining silent killer with low survival rates for tumor growth that advances undetected till later stages.

https://www.medidect.com/wp-content/uploads/2025/01/chart.png
One million (74%) cancer deaths are for cancers for which there is no structured Preventive Oncology Program across India.
https://www.medidect.com/wp-content/uploads/2025/01/chart.png

The Solution

Introducing multi-tumor screening blood test for asymptomatic healthy individuals

https://www.medidect.com/wp-content/uploads/2023/07/PanTum-Logo-640x99.png

PanTum Detect screens healthy adults for dangerous tumors covering all solid cancers

https://www.medidect.com/wp-content/uploads/2024/06/PanTumLab.png

SAFE, ACCURATE AND CLINICALLY PROVEN GERMAN TECHNOLOGY

0123456789001234567890                     .01234567890                     %
Sensitivity*
*Sensitivity: True positives
0123456789001234567890                     %
Specificity*
* Specificity: True negatives
0123456789001234567890                     +
Publications
01234567890                     ,012345678900123456789001234567890                     +
Candidate Studies
012345678900123456789001234567890                     ,012345678900123456789001234567890                     +
Tests performed globally

Introducing Cancer-Scan Program Initiated by pre-testing with PanTum Detect

https://www.medidect.com/wp-content/uploads/2024/01/PanTumAsset-6-640x423.png
Combines pre-testing and targeted follow-up cancer diagnostics only for those screened candidates that test positive with PanTum Detect blood test.

Innovative & Unique

The EDIM technology is backed by science and more than 20 years of research

Leveraging the immune system to deliver high accuracy of PanTum® Detect test

EDIM (Epitope Detected in Monocytes) Technology detects elevated levels of enzyme tumor biomarkers (Apo10 & TKTL-1) in macrophages. It leverages on our innate immune system, wherein macrophages do a biological biopsy and engulf universal enzyme tumor biomarkers (Apo10 & TKTL-1) when they phagocytose degenerated tumor cells.

https://www.medidect.com/wp-content/uploads/2023/04/EDIM1.png
https://www.medidect.com/wp-content/uploads/2023/04/EDIM1.png

Leveraging the immune system to deliver high accuracy of PanTum® Detect test

The human immune system is first to recognize the progression of disease, even before the onset of symptoms. EDIM® (Epitope Detection in Monocytes/Macrophages) technology makes the information contained in the human immune system visible for detection of cancer. Higher than normal levels of Apo10 (DNaseX) & TKTL1 detected in immune cells (macrophages) of screened individuals gives an indication of potential cancer and pre-cancer lesions in early and symptomless stages for healthy individuals.